Alzheimer's disease: Clinical trials to watch

Authors

Marwan Noel Sabbagh, Alzheimer's and Memory Disorders Division, Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. Electronic address: neuropub@barrowneuro.org.
Jessica Kennedy, Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Jad Majeed, Undergraduate Program, University of Arizona, Tucson, AZ, USA.
Boris Decourt, Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Document Type

Article

Abstract

Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events. Here we highlight several ongoing clinical trials, aiming to develop therapeutic agents with higher efficacy and better safety profiles including third-generation ATTs, aggregation inhibitors, Sigma-1 receptor agonists, anti-tau antisense oligonucleotides, and GLP-1 receptor agonists.

Medical Subject Headings

Alzheimer Disease (drug therapy); Humans; Clinical Trials as Topic; Oligonucleotides, Antisense (therapeutic use); Glucagon-Like Peptide-1 Receptor Agonists; Amyloid beta-Peptides (antagonists & inhibitors); tau Proteins (antagonists & inhibitors)

Publication Date

8-8-2025

Publication Title

Med (New York, N.Y.)

E-ISSN

2666-6340

Volume

6

Issue

8

First Page

100771

PubMed ID

40782673

Digital Object Identifier (DOI)

10.1016/j.medj.2025.100771

Recommended Citation

Sabbagh, Marwan Noel; Kennedy, Jessica; Majeed, Jad; and Decourt, Boris, "Alzheimer's disease: Clinical trials to watch" (2025). Neurology. 2003.
https://scholar.barrowneuro.org/neurology/2003